HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-dose Ara-C can cause complete remission of acute non-lymphocytic leukemia: differentiation induction?

Abstract
Fourteen patients with acute nonlymphocytic leukemia were treated with low-dose arabinosylcytosine (LDAC). Thirteen patients received subcutaneous injections at a dose of 10 mg/M2 every 12 h. One patient received 25 mg intramuscularly daily. All cases received one to three courses with each course lasting 10-60 days (median 19). Complete remission was achieved in 6 (or 43%) of the patients. Three patients had only cytoreduction and 5 patients did not respond. During the therapy severe thrombocytopenia occurred in all patients while prominent other cytopenias occurred in 10. Two-thirds of the patients achieving a remission had significant myelosuppression. There was one treatment-related death. During therapy 11 patients demonstrated a decrease in leukemia cells with an associated increase in differentiated granulocytes. This included 3 of the 4 complete remitters, and 3 of the 5 nonresponders. These results seem to suggest that the therapeutic effect of low-dose Ara-C may result from a combination of differentiation induction, cytotoxicity and unusual sensitivity of the leukemic cells to this agent.
AuthorsJ S Ye, G H Feng, G R Liang, M X Tao
JournalLeukemia research (Leuk Res) Vol. 10 Issue 10 Pg. 1221-4 ( 1986) ISSN: 0145-2126 [Print] England
PMID3773565 (Publication Type: Journal Article)
Chemical References
  • Cytarabine
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Bone Marrow (pathology)
  • Cell Differentiation (drug effects)
  • Child, Preschool
  • Cytarabine (pharmacology, therapeutic use)
  • Female
  • Humans
  • Leukemia (drug therapy, pathology)
  • Male
  • Middle Aged
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: